anastrozole News - LARVOL Sigma

«1 2...13 14 15 16 171819 20 21 22 23...41 42 »

|||||||||| anastrozole / Generic mfg.
[VIRTUAL] Anastrozole improves height prediction and near final height as monotherapy or in combination with growth hormone () - Aug 27, 2021 - Abstract #ESPE2021ESPE_897;
Anastrozole therapy was safe and effective in improving the PFH and NFH in boys with poor height prediction, either as monotherapy or in combination with growth hormone.

||||||||||  Bizengri (zenocutuzumab-zbco) / Merus, Partner Therap
Trial completion date, Trial primary completion date:  MCLA-128-CL02: MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. (clinicaltrials.gov) -  Aug 26, 2021
P2, N=101, Active, not recruiting,  Sponsor: Merus N.V.
Anastrozole therapy was safe and effective in improving the PFH and NFH in boys with poor height prediction, either as monotherapy or in combination with growth hormone. Trial completion date: Jul 2022 --> Dec 2022 | Trial primary completion date: Jul 2020 --> Dec 2021

|||||||||| fulvestrant / Generic mfg.
Clinical, Journal: A Case of Breast Mucinous Carcinoma with Bladder Metastasis Effectively Treated with Endocrine Therapy and Chemotherapy (Pubmed Central) - Aug 25, 2021
However, 2 years and 8 months after diagnosis of bladder metastasis, the patient showed disease progression and decided to discontinue all chemotherapy and pursue palliative care. We also present a review and discussion of the relevant literature.

|||||||||| anastrozole / Generic mfg.
Clinical, Journal: Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. (Pubmed Central) - Aug 20, 2021
P3
In postmenopausal women with hormone-receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy, extending hormone therapy by 5 years provided no benefit over a 2-year extension but was associated with a greater risk of bone fracture. (Funded by AstraZeneca and the Austrian Breast and Colorectal Cancer Study Group; ABCSG-16/SALSA ClinicalTrials.gov number, NCT00295620.).

|||||||||| anastrozole / Generic mfg.
Biomarker, Clinical, Journal: Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. (Pubmed Central) - Aug 19, 2021
This model was not validated in an independent dataset but that dataset was clinically and genomically substantially different. The model will need validation in a prospective study.

||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date, Metastases:  Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) -  Aug 18, 2021
P3, N=1050, Recruiting,  Sponsor: Borstkanker Onderzoek Groep
The model will need validation in a prospective study. Trial primary completion date: Apr 2021 --> Aug 2022

|||||||||| anastrozole / Generic mfg.
Preclinical, Journal: Determining the Interaction Behavior of Calf Thymus DNA with Anastrozole in the Presence of Histone H1: Spectroscopies and Cell Viability of MCF-7 Cell Line Investigations. (Pubmed Central) - Aug 14, 2021
The intercalation of anastrozole to ct DNA seemed to be significantly related to an induced reduction in MCF-7 cell proliferation. The molecular modeling results have suggested that anastrozole could bind to H1 in ct DNA-H1 complex in ternary systems, which supports the conclusions that have been obtained from experimental data.

|||||||||| anastrozole / Generic mfg., melphalan / Generic mfg.
Journal: Molecular Insights into the Loading and Dynamics of Anticancer Drugs on Silicene and Folic acid-conjugated Silicene nanosheets: DFT calculation and MD simulation. (Pubmed Central) - Aug 13, 2021
Also, the obtained results demonstrate that the movement of drug molecules toward the carriers is spontaneous. Our study provides insights into the drug delivery capability of SNS and FA-SNS for the delivery of two drugs (ANA and MEL).

|||||||||| tamoxifen / Generic mfg.
Clinical, Journal: PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial. (Pubmed Central) - Aug 12, 2021
PAM-50 can be used as a prognostic tool for local recurrence risk in postmenopausal women with hormone receptor-positive breast cancer treated with endocrine therapy. The test was not predictive for the benefit of radiotherapy.

|||||||||| Ibrance (palbociclib) / Pfizer
Clinical: Tthe phase 2 NeoPalAna trial enrolled patients w/ stage II and III ER-positive, HER2-negative breast cancer & saw complete cell cycle arrest rate increase to 87% after 2 weeks of treatment w/ anastrozole/palbociclib @BCJoyceO @TexasOncology @gotoPER #bcsm https://t.co/xZLtctgjZo (Twitter) - Aug 8, 2021

|||||||||| tamoxifen / Generic mfg.
Journal: Role of Persistent Organic Pollutants in Breast Cancer Progression and Identification of Estrogen Receptor Alpha Inhibitors Using In-Silico Mining and Drug-Drug Interaction Network Approaches. (Pubmed Central) - Aug 7, 2021
Based on the lowest-scoring values, ZINC08441573, ZINC00664754, ZINC00702695, ZINC00627464, and ZINC08440501 (synthetic compounds), and capsaicin, flavopiridol tectorgenin, and ellagic acid (natural compounds) showed incredible interactions with the active sites of ERα, even more convening and resilient than standard breast cancer drugs Tamoxifen, Arimidex and Letrozole. Our findings confirm the role of POPs in breast cancer progression and suggest that natural and synthetic compounds with high binding affinity could be more efficient and appropriate candidates to treat breast cancer after validation through in vitro and in vivo studies.

|||||||||| anastrozole / Generic mfg.
[VIRTUAL] A DNA methylation signature to paternal germline age and association with infertility. () - Aug 5, 2021 - Abstract #AUA2021AUA_2481;
This finding provides further evidence that environmental and epigenetic factors contribute to the health of sperm. If replicated, this use of epigenetic profiling to predict sperm health will become a useful tool in informing discussions with patients regarding the impact of lifestyle and paternal preconception health on fertility success.

|||||||||| anastrozole / Generic mfg.
Journal: Rescuing Dicer expression in inflamed colon tissues alleviates colitis and prevents colitis-associated tumorigenesis. (Pubmed Central) - Aug 4, 2021
Anastrozole, berberine, and pranoprofen alleviated colitis and colitis-associated tumorigenesis by promoting Dicer expression. Our study provides insight into potential colitis treatment and colitis-associated colon cancer prevention strategies.

|||||||||| tamoxifen / Generic mfg.
Journal: Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. (Pubmed Central) - Aug 4, 2021
However, the EP, BCI, and particularly ROR scores are determined largely by proliferative features. These relationships help to explain the differences in the prognostic performance of the tests.

||||||||||  Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date:  PREDIX LumB: Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (clinicaltrials.gov) -  Aug 3, 2021
P2, N=181, Active, not recruiting,  Sponsor: Thomas Hatschek
These relationships help to explain the differences in the prognostic performance of the tests. Recruiting --> Active, not recruiting | Trial completion date: Jun 2031 --> Dec 2031 | Trial primary completion date: Dec 2021 --> Jul 2021

||||||||||  Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial primary completion date, Combination therapy:  PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (clinicaltrials.gov) -  Aug 3, 2021
P2, N=84, Active, not recruiting,  Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting | Trial completion date: Jun 2031 --> Dec 2031 | Trial primary completion date: Dec 2021 --> Jul 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2022 --> Apr 2021

||||||||||  Ibrance (palbociclib) / Pfizer
New P2 trial, Circulating tumor DNA:  TRAK-ER: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (clinicaltrials.gov) -  Aug 1, 2021
P2, N=1100, Not yet recruiting,  Sponsor: Royal Marsden NHS Foundation Trust

|||||||||| tamoxifen / Generic mfg.
Clinical, Journal, HEOR: Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study. (Pubmed Central) - Jul 30, 2021
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2022 --> Apr 2021 It is feasible to forecast the effects of treatments on HRQOL even when the time series is short.

|||||||||| anastrozole / Generic mfg.
Conversely, I gained 40 pounds during my 5 years on Arimidex & still haven’t lost it, 14 years post-diagnosis. I’m 5’0 & weighed 110 lbs. when I found out I had breast cancer. Still incredibly grateful to be alive, though 🙏🏻 (Twitter) - Jul 29, 2021

|||||||||| tamoxifen / Generic mfg., fulvestrant / Generic mfg.
Review, Journal: Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. (Pubmed Central) - Jul 28, 2021
The PI3K/AKT/mTOR pathway is implicated in sustaining endocrine resistance and has become the target of many new drugs for ER+ breast cancer. This article reviews the function of the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway and the various classes of PI3K pathway inhibitors that have been developed to disrupt this pathway signaling for the treatment of hormone-receptor-positive breast cancer.

|||||||||| Ibrance (palbociclib) / Pfizer
[VIRTUAL] Treatment patterns in black and indigenous people and people of color (BIPOC) receiving palbociclib for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in a real-world setting: POLARIS study results () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1697;
P=N/A
PAL was routinely prescribed in clinical practice for BIPOC, with the majority of patients initiating PAL at the recommended 125-mg dose. PAL was well tolerated, with similar rates of dose modifications and AEs regardless of tx partner.

|||||||||| everolimus / Generic mfg.
[VIRTUAL] BOLERO-5: A phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER+/HER2- advanced breast cancer () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1625;
P2
BOLERO-5 is a randomized, double-blind, placebo controlled, phase II trial comparing EVE (10 mg qd) or placebo (PBO) in combination with EXE (25 mg qd). The efficacy and safety of BOLERO-5 validate the findings from BOLERO-2, and further support the use of EVE + EXE in Chinese post-menopausal women with ER+, HER2- ABC.

|||||||||| Ibrance (palbociclib) / Pfizer
[VIRTUAL] Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study (Channel 1) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1279;
P2
Interim analysis data demonstrated superior anti-proliferative activity of giredestrant compared with A. Safety was consistent with the known giredestrant profile. Hoffmann-La Roche Ltd.

|||||||||| anastrozole / Generic mfg.
Clinical, Journal: Secondary azoospermia after sleeve gastrectomy: a case report. (Pubmed Central) - Jul 20, 2021
Hormonal therapy with anastrozole for 10 months and diagnostic testicular biopsy...Testicular histopathology revealed the presence of Sertoli cells only. Although further research is need to determine the relationship between sleeve gastrectomy and secondary infertility, men should be informed of the potentially deleterious effects of this surgery on semen parameters.

||||||||||  Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases:  Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (clinicaltrials.gov) -  Jul 19, 2021
P2, N=327, Active, not recruiting,  Sponsor: Novartis Pharmaceuticals
Although further research is need to determine the relationship between sleeve gastrectomy and secondary infertility, men should be informed of the potentially deleterious effects of this surgery on semen parameters. Trial primary completion date: Jun 2021 --> Feb 2022

||||||||||  camizestrant (AZD9833) / AstraZeneca
New P3 trial, Circulating tumor DNA:  Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (clinicaltrials.gov) -  Jul 15, 2021
P3, N=302, Recruiting,  Sponsor: AstraZeneca

||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg.
Trial completion:  Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole (clinicaltrials.gov) -  Jul 15, 2021
P4, N=79, Completed,  Sponsor: Stanford University
Trial primary completion date: Jun 2021 --> Feb 2022 Recruiting --> Completed

||||||||||  giredestrant (GDC-9545) / Roche
Enrollment closed:  coopERA BC: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) (clinicaltrials.gov) -  Jul 14, 2021
P2, N=221, Active, not recruiting,  Sponsor: Hoffmann-La Roche
Recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Ibrance (palbociclib) / Pfizer
Enrollment closed, HEOR, Patient reported outcomes, Metastases:  PRECYCLE: Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (clinicaltrials.gov) -  Jul 14, 2021
P4, N=960, Active, not recruiting,  Sponsor: Palleos Healthcare GmbH
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

|||||||||| anastrozole / Generic mfg.
Journal: Aromatase inhibitor anastrozole modifies cellular functions in gingival fibroblasts and endothelial cells: possible periodontal complications of aromatase inhibitor treatment. (Pubmed Central) - Jul 14, 2021
Recruiting --> Active, not recruiting These results suggest that anastrozole modulates various cellular functions in HGFs and endothelial cells.

||||||||||  Imfinzi (durvalumab) / AstraZeneca
Trial primary completion date, Combination therapy:  Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer (clinicaltrials.gov) -  Jul 8, 2021
P2, N=17, Active, not recruiting,  Sponsor: H. Lee Moffitt Cancer Center and Research Institute
These results suggest that anastrozole modulates various cellular functions in HGFs and endothelial cells. Trial primary completion date: Mar 2022 --> Nov 2020

|||||||||| Verzenio (abemaciclib) / Eli Lilly
[VIRTUAL] Drug-induced liver injury from abemaciclib () - Jul 7, 2021 - Abstract #GSS2021GSS_97;
This subsequently led to an increase in transaminases, intrahepatic cholestasis, bilirubin conjugation disorder and significantly reduced hepatic synthesis. Summary A drug-toxic hepatopathy caused by abemaciclib can be assumed.

||||||||||  Apristor (onapristone XR) / Context Therap
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Pan tumor:  A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone (clinicaltrials.gov) -  Jul 7, 2021
P2, N=43, Recruiting,  Sponsor: Memorial Sloan Kettering Cancer Center
Summary A drug-toxic hepatopathy caused by abemaciclib can be assumed. N=84 --> 43 | Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Apr 2022 --> Apr 2023

||||||||||  Eligard (leuprolide acetate) / Tolmar, Sanofi
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy:  OVELIA: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (clinicaltrials.gov) -  Jul 5, 2021
P3, N=250, Recruiting,  Sponsor: Tolmar Inc.
N=84 --> 43 | Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Apr 2022 --> Apr 2023 Not yet recruiting --> Recruiting | Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Sep 2023 --> Dec 2023

|||||||||| letrozole / Generic mfg., anastrozole / Generic mfg.
Clinical, Journal: Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer. (Pubmed Central) - Jul 3, 2021
Carriers of OPG rs2073618 may be at increased risk of AIMSS. If confirmed in other cohorts, OPG genotyping can be used to identify individuals with HR + early breast cancer in whom alternate endocrine therapy or interventions to enhance symptom detection and implement strategies to reduce musculoskeletal symptoms may be needed.

|||||||||| Revlimid (lenalidomide) / BMS, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] CONSTRUCTION OF AN INFORMATION GUIDE FOR THE MANAGEMENT OF ANTINEOPLASTIC AND SUPPORT DRUGS VIA PROBE. () - Jul 2, 2021 - Abstract #ICUC2021ICUC_306;
The information provided by the information guide is intended to support oncology professionals in prescribing and correctly administering oral solids via enteral tube. In the literature review, important points such as the use of an oral meter, a device that ensures accuracy and reduces waste, and the correct location of the probe were emphasized in this guide.

||||||||||  denifanstat (TVB-2640) / Sagimet Biosci
Trial completion date, Trial primary completion date:  TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) -  Jul 1, 2021
P2, N=80, Recruiting,  Sponsor: Mayo Clinic
In the literature review, important points such as the use of an oral meter, a device that ensures accuracy and reduces waste, and the correct location of the probe were emphasized in this guide. Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2021 --> Jul 2022

|||||||||| tamoxifen / Generic mfg.
Clinical, Observational data, Journal: The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies. (Pubmed Central) - Jul 1, 2021
The lack of interaction between BMI and treatment group on breast cancer risk suggests women are likely to experience benefit from preventive therapy regardless of their BMI. Trial registration Both trials were registered [IBIS-I: ISRCTN91879928 on 24/02/2006, retrospectively registered ( http://www.isrctn.com/ISRCTN91879928 ); IBIS-II: ISRCTN31488319 on 07/01/2005, retrospectively registered ( http://www.isrctn.com/ISRCTN31488319 )].

||||||||||  Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date:  Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast (clinicaltrials.gov) -  Jun 29, 2021
P1/2, N=36, Recruiting,  Sponsor: Icahn School of Medicine at Mount Sinai
Trial registration Both trials were registered [IBIS-I: ISRCTN91879928 on 24/02/2006, retrospectively registered ( http://www.isrctn.com/ISRCTN91879928 ); IBIS-II: ISRCTN31488319 on 07/01/2005, retrospectively registered ( http://www.isrctn.com/ISRCTN31488319 )]. Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2022

|||||||||| anastrozole / Generic mfg.
[VIRTUAL] Burning pain and burning cigarettes: A persistent pain service survey of smoking cessation needs. () - Jun 29, 2021 - Abstract #IASP2021IASP_410;
Canberra AIHW.2019AIHW[1], but in mental health services prevalence is reported to be as high as 57% ADDIN EN.CITE Plever20205774[6]5774577417Plever, S.McCarthy, I.Anzolin, M.Emmerson, B.Allan, J.Hay, K.The QLD Mental Health Clinical Collaborative, Metro North Mental Health, Windsor, QLD, Australia._x000D_Metro North Mental Health, Metro North Hospital and Health Service, Brisbane, QLD, Australia._x000D_Mental Health Alcohol and Other Drugs Branch, Clinical Excellence Queensland, Herston, QLD, Australia._x000D_Statistics Unit, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.Queensland smoking care in adult acute mental health inpatient units: Supporting practice changeAust N Z J Psychiatry< /titles >Australian and New Zealand Journal of PsychiatryAust...Persistent pain services need local, current data to inform whether smoking cessation should be included and similarly prioritised in their services. Previous research in American cohorts has linked smoking to higher persistent pain scores, poorer pain-related function, worse occupational outcomes and increased opioid use relative to non-smokers ADDIN EN.CITE ADDIN EN.CITE.DATA 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 565

|||||||||| paclitaxel / Generic mfg.
[VIRTUAL] Kinin B1 and B2 Receptors Contribute to the Breast Cancer- Associated Pain () - Jun 29, 2021 - Abstract #IASP2021IASP_277;
Moreover, the kinin B1 receptor antagonist seems to reduce breast cancer cell proliferation. Thus, kinin receptor antagonists could be promising to reduce breast tumor proliferation and still treat the painful symptoms caused by it and its therapy.

|||||||||| anastrozole / Generic mfg.
Journal: Management of Aromatase Inhibitor-Induced Musculoskeletal Symptoms. (Pubmed Central) - Jun 26, 2021
Aromatase inhibitor-induced musculoskeletal symptoms (AIMSS) were first recognized as a distinct entity in 2001, 5 years after the approval of the first aromatase inhibitor, anastrozole...Several interventions for managing AIMSS have been investigated in the last decade, with some demonstrating promise. This article provides an evidence-based summary to guide practicing oncologists in regard to the epidemiology, prevention, and treatment of AIMSS.

||||||||||  NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Metastases:  POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) -  Jun 25, 2021
P2, N=29, Recruiting,  Sponsor: Dartmouth-Hitchcock Medical Center
This article provides an evidence-based summary to guide practicing oncologists in regard to the epidemiology, prevention, and treatment of AIMSS. Trial completion date: Dec 2021 --> Apr 2022 | Trial primary completion date: Aug 2021 --> Jan 2022

|||||||||| Verzenio (abemaciclib) / Eli Lilly
Clinical, Journal: Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. (Pubmed Central) - Jun 24, 2021
P3
While higher rates of adverse events were reported in older patients, they were manageable with dose adjustments and concomitant medication. Importantly, a consistent efficacy benefit was observed across all age groups.

|||||||||| letrozole / Generic mfg., anastrozole / Generic mfg.
Retrospective data, Review, Journal: A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility. (Pubmed Central) - Jun 22, 2021
Either steroidal (Testolactone) or nonsteroidal (Anastrozole and Letrozole) aromatase inhibitors were found to statistically improve all the evaluated hormonal and seminal outcomes with a safe tolerability profile. While the evidence is promising, future prospective randomized placebo-controlled multicenter trials are necessary to better define the efficacy of these medications.

|||||||||| tamoxifen / Generic mfg.
Clinical, Journal, Monotherapy: The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer. (Pubmed Central) - Jun 22, 2021
Our results demonstrated a high difference in all parameters in patients receiving aromatase inhibitors compared to tamoxifen group and controls. Aromatase inhibitors, which reduce estrogen levels in the blood, might affect the tear functions more than tamoxifen, which affects as antiestrogenic on estrogen receptors.

|||||||||| everolimus / Generic mfg.
Clinical, Journal, Real-world evidence: Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer. (Pubmed Central) - Jun 22, 2021
As new drugs become available, it is crucial to understand the adverse events and potential complications associated with the use of such drugs in the general population, outside of the controlled clinical trial setting. This study describes the patterns of everolimus use and adverse events, including hospitalization and emergency room visits, in a large cohort of patients with metastatic breast cancer in routine practice.

|||||||||| Verzenio (abemaciclib) / Eli Lilly
Clinical, Journal, HEOR: Health-Related Quality of Life in MONARCH 3: Abemaciclib Plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. (Pubmed Central) - Jun 22, 2021
P3
These results also complement previously reported toxicity data, as measured by investigator-assessed adverse events. Taken together, these results support treatment with abemaciclib plus NSAI for postmenopausal women with HR+, HER2- ABC.

|||||||||| finasteride / Generic mfg.
Preclinical, Journal: Effects of Testosterone on the Expression of Connexin 26 and Connexin 43 in the Uterus of Rats During Early Pregnancy. (Pubmed Central) - Jun 22, 2021
Taken together, these results support treatment with abemaciclib plus NSAI for postmenopausal women with HR+, HER2- ABC. Changes in the uterine connexin 26 and connexin 43 expression by testosterone could disrupt embryo implantation, resulting in early pregnancy loss.

|||||||||| exemestane / Generic mfg.
Clinical, Journal: Exemestane induced cholestatic liver injury - A case report. (Pubmed Central) - Jun 22, 2021
Hepatotoxicity with aromatase inhibitors have rarely been reported in clinical trials and to date, instances of exemestane induced hepatotoxicity has only been reported in two case reports. The patient's history of primary biliary cirrhosis may be an important risk factor for the development of hepatotoxicity from exemestane.



	Diseases Companies Products Productz Mechanisms of Action Sites